{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:00:22Z","timestamp":1781726422039,"version":"3.54.5"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bulcan.2026.03.016","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:49:05Z","timestamp":1781725745000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques dans la my\u00e9lofibrose\u00a0: s\u00e9lection des patients, pr\u00e9paration pr\u00e9-greffe et harmonisation des pratiques (SFGM-TC)"],"prefix":"10.1016","author":[{"given":"Ga\u00eblle","family":"Vertenoeil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Desmier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Masouridi-Levrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"M\u00e9diavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Souchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Loschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9onardo","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Cornillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bulcan.2026.03.016_bib0485","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11899-014-0228-z","article-title":"Epidemiology of MPN: what do we know?","volume":"9","author":"Anderson","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"13","key":"10.1016\/j.bulcan.2026.03.016_bib0490","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2026.03.016_bib0495","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2026.03.016_bib0500","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2026.03.016_bib0505","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.bulcan.2026.03.016_bib0510","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2026.03.016_bib0515","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bulcan.2026.03.016_bib0520","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bulcan.2026.03.016_bib0525","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ajh.27226","article-title":"Comparative clinical and molecular landscape of primary and secondary myelofibrosis: superior performance of MIPSS70+ v2.0\u00a0over MYSEC-PM","volume":"99","author":"Guerra","year":"2024","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.bulcan.2026.03.016_bib0530","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN International Working Group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bulcan.2026.03.016_bib0535","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.bulcan.2026.03.016_bib0540","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65\u00a0years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.016_bib0545","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Kr\u00f6ger","year":"2024","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.bulcan.2026.03.016_bib0550","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/bloodadvances.2024014368","article-title":"Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis","volume":"9","author":"Luque Paz","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.bulcan.2026.03.016_bib0555","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.2024025459","article-title":"Current myeloproliferative neoplasm scoring systems for clinical practice","volume":"145","author":"Pasquer","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.016_bib0560","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1\u00a0mutations: a FIM study","volume":"5","author":"Luque Paz","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.016_bib0565","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.27136","article-title":"The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53\u00a0mutations to mutation-enhanced international prognostic score systems (MIPSS70\/plus\/plus v2.0) for primary myelofibrosis","volume":"99","author":"Loscocco","year":"2024","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.bulcan.2026.03.016_bib0570","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ajh.27609","article-title":"TP53\u00a0mutations in myeloproliferative neoplasms: context-dependent evaluation of prognostic relevance","volume":"100","author":"Tefferi","year":"2025","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1016\/j.bulcan.2026.03.016_bib0575","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1182\/bloodadvances.2020002727","article-title":"Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.bulcan.2026.03.016_bib0580","first-page":"2901","article-title":"Impact of TP53\u00a0on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation","volume":"141","author":"Gagelmann","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.016_bib0585","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1038\/s41467-025-60884-1","article-title":"JAK2\u00a0inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms","volume":"16","author":"Maslah","year":"2025","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.bulcan.2026.03.016_bib0590","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A prognostic model to predict survival after 6\u00a0months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.bulcan.2026.03.016_bib0595","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1182\/bloodadvances.2022008158","article-title":"RR6\u00a0prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort","volume":"6","author":"Scalzulli","year":"2022","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.bulcan.2026.03.016_bib0600","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11247418","article-title":"Prediction of survival and prognosis migration from gold-standard scores in myelofibrosis patients treated with ruxolitinib applying the RR6 prognostic model in a monocentric real-life setting","volume":"11","author":"Duminuco","year":"2022","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.bulcan.2026.03.016_bib0605","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.3324\/haematol.2024.285098","article-title":"Validation and molecular integration of the RR6\u00a0model to predict survival after 6\u00a0months of therapy with ruxolitinib","volume":"109","author":"Coltro","year":"2024","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.bulcan.2026.03.016_bib0610","doi-asserted-by":"crossref","first-page":"e70062","DOI":"10.1002\/cncr.70062","article-title":"Revised \u201ciRR6\u201d model in intermediate-1\u00a0risk myelofibrosis patients treated with ruxolitinib","volume":"131","author":"Palandri","year":"2025","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.016_bib0615","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14796694.2025.2454895","article-title":"Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib","volume":"21","author":"Passamonti","year":"2025","journal-title":"Future Oncol"},{"issue":"20","key":"10.1016\/j.bulcan.2026.03.016_bib0620","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bulcan.2026.03.016_bib0625","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1182\/bloodadvances.2023009886","article-title":"A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR\/EBMT analysis","volume":"7","author":"Tamari","year":"2023","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.bulcan.2026.03.016_bib0630","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood.2024027287","article-title":"Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis","volume":"145","author":"Hern\u00e1ndez-Boluda","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.016_bib0635","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/ajh.27262","article-title":"Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: a study on behalf of the Chronic Malignancies Working Party of EBMT","volume":"99","author":"Polverelli","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.016_bib0640","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410\u00a0patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.bulcan.2026.03.016_bib0645","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1182\/bloodadvances.2024012880","article-title":"Treatment approach and outcomes of patients with accelerated\/blast-phase myeloproliferative neoplasms in the current era","volume":"8","author":"Patel","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.bulcan.2026.03.016_bib0650","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/bloodadvances.2021006827","article-title":"Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis","volume":"6","author":"Gagelmann","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.bulcan.2026.03.016_bib0655","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ajh.26833","article-title":"Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"98","author":"Ort\u00ed","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.03.016_bib0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.07.026","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70\u00a0years or older: a study from the German Registry for Stem Cell Transplantation","volume":"30","author":"Gagelmann","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.bulcan.2026.03.016_bib0665","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jtct.2022.01.018","article-title":"Optimal timing of allogeneic stem cell transplantation for primary myelofibrosis","volume":"28","author":"Cipkar","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.bulcan.2026.03.016_bib0670","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3324\/haematol.2009.011429","article-title":"Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study","volume":"95","author":"Alessandrino","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.016_bib0675","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jtct.2020.11.007","article-title":"Iron toxicity and chelation therapy in hematopoietic stem cell transplant","volume":"27","author":"Isidori","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.016_bib0680","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/ejh.13689","article-title":"Effect of pre-transplant JAK1\/2\u00a0inhibitors and CD34\u00a0dose on transplant outcomes in myelofibrosis","volume":"107","author":"Cyriac","year":"2021","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.bulcan.2026.03.016_bib0685","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/ajh.26654","article-title":"Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis","volume":"97","author":"Perram","year":"2022","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.bulcan.2026.03.016_bib0690","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/bmt.2012.249","article-title":"Effects of spleen status on early outcomes after hematopoietic cell transplantation","volume":"48","author":"Akpek","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2026.03.016_bib0695","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbmt.2017.03.002","article-title":"The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Robin","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2026.03.016_bib0700","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","article-title":"Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study","volume":"36","author":"Kunte","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.016_bib0705","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajh.26020","volume":"96","author":"Polverelli","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.016_bib0710","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S2352-3026(22)00330-1","article-title":"Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"10","author":"Polverelli","year":"2023","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.bulcan.2026.03.016_bib0715","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","article-title":"Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT","volume":"35","author":"Kr\u00f6ger","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bulcan.2026.03.016_bib0720","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/bmt.2013.173","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1\u00a0and JAK2\u00a0inhibitor ruxolitinib","volume":"49","author":"Jaekel","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2026.03.016_bib0725","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2\u00a0study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.03.016_bib0730","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41409-024-02464-3","article-title":"Fedratinib as an alternative to splenectomy for refractory splenomegaly prior to transplant for myelofibrosis","volume":"60","author":"England","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2026.03.016_bib0735","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3\u00a0trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.03.016_bib0740","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.016_bib0745","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.bbmt.2018.12.064","article-title":"Busulfan- or thiotepa-based conditioning in myelofibrosis: a phase II multicenter randomized study from the GITMO group","volume":"25","author":"Patriarca","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2026.03.016_bib0750","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41409-024-02220-7","article-title":"Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation","volume":"59","author":"Oechsler","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2026.03.016_bib0755","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3\u00a0decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.016_bib0760","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/ajh.27252","article-title":"Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: a global collaborative analysis","volume":"99","author":"Gagelmann","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.016_bib0765","doi-asserted-by":"crossref","first-page":"100964","DOI":"10.1016\/j.adro.2022.100964","article-title":"Pretransplant splenic irradiation in patients with myeloproliferative neoplasms","volume":"7","author":"Ponce","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.03.016_bib0770","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12032-019-1245-5","article-title":"Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis","volume":"36","author":"Helbig","year":"2019","journal-title":"Med Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2026.03.016_bib0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.05.023","article-title":"Pilot study of low-dose splenic irradiation and transplantation in JAK inhibitor-refractory myelofibrosis with splenomegaly","volume":"31","author":"Rathje","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.bulcan.2026.03.016_bib0780","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00262-025-04046-8","article-title":"Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis","volume":"74","author":"Villar","year":"2025","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"10.1016\/j.bulcan.2026.03.016_bib0785","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","article-title":"Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation","volume":"24","author":"Kr\u00f6ger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.016_bib0790","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/bloodadvances.2021005035","article-title":"Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study","volume":"6","author":"Ali","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.bulcan.2026.03.016_bib0795","doi-asserted-by":"crossref","DOI":"10.1200\/OA-25-00020","article-title":"Phase II study of peri- and post-transplant ruxolitinib for patients with myelofibrosis receiving allogeneic hematopoietic cell transplantation","volume":"2","author":"Hobbs","year":"2025","journal-title":"JCO Oncol Adv"},{"issue":"2","key":"10.1016\/j.bulcan.2026.03.016_bib0800","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ajh.27529","article-title":"Clinical and immune effects of peri-transplantation JAK inhibition for myelofibrosis","volume":"100","author":"Rathje","year":"2025","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.016_bib0805","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-023-00878-8","article-title":"Blast phase myeloproliferative neoplasm: contemporary review and 2024\u00a0treatment algorithm","volume":"13","author":"Tefferi","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.016_bib0810","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010011","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment considerations and unmet needs","volume":"15","author":"Liu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.bulcan.2026.03.016_bib0815","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11739-010-0413-6","article-title":"Splanchnic vein thrombosis: clinical presentation, risk factors and treatment","volume":"5","author":"De Stefano","year":"2010","journal-title":"Intern Emerg Med"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.016_bib0820","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3350\/cmh.2019.0078","article-title":"Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with myeloproliferative neoplasms","volume":"26","author":"Lee","year":"2020","journal-title":"Clin Mol Hepatol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.03.016_bib0825","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.bbmt.2012.04.011","article-title":"Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation","volume":"18","author":"Wong","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2026.03.016_bib0830","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/bjh.19214","article-title":"Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: a study on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"204","author":"Robin","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.016_bib0835","first-page":"103476","volume":"73","author":"Battipaglia","year":"2025","journal-title":"Curr Res Transl Med"},{"issue":"7","key":"10.1016\/j.bulcan.2026.03.016_bib0840","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"58","author":"Mohty","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2026.03.016_bib0845","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41409-025-02570-w","volume":"60","author":"Ravaioli","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.016_bib0850","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2468-1253(19)30047-0","article-title":"Porto-sinusoidal vascular disease: proposal and description of a novel entity","volume":"4","author":"De Gottardi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.bulcan.2026.03.016_bib0855","article-title":"Pulmonary arterial hypertension (PAH) is associated with increased non-relapse mortality after allogeneic hematopoietic cell transplantation (allo HCT) for myelofibrosis","volume":"25","author":"Gupta Rohan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2026.03.016_bib0860","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.leukres.2014.01.014","article-title":"Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms","volume":"38","author":"Christensen","year":"2014","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.bulcan.2026.03.016_bib0865","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.3324\/haematol.2018.208876","article-title":"Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy","volume":"104","author":"Fukuda","year":"2019","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.bulcan.2026.03.016_bib0870","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164086","article-title":"Kidney dysfunction is associated with thrombosis and disease severity in myeloproliferative neoplasms: implications from the German Study Group for MPN Bioregistry","volume":"13","author":"Gecht","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.bulcan.2026.03.016_bib0875","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s00277-020-04239-4","article-title":"Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis","volume":"99","author":"Lucijanic","year":"2020","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.016_bib0880","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jtct.2021.02.030","article-title":"Impact of pretransplantation renal dysfunction on outcomes after allogeneic hematopoietic cell transplantation","volume":"27","author":"Farhadfar","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.bulcan.2026.03.016_bib0885","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","article-title":"Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the chronic malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"McLornan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2026.03.016_bib0890","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1097\/HS9.0000000000000784","article-title":"High molecular and cytogenetic risk in myelofibrosis does not benefit from higher intensity conditioning before hematopoietic cell transplantation: an International Collaborative Analysis","volume":"6","author":"Gagelmann","year":"2022","journal-title":"Hemasphere"},{"issue":"6","key":"10.1016\/j.bulcan.2026.03.016_bib0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.03.006","article-title":"Non-myeloablative allogeneic hematopoietic stem cell transplantation for myelofibrosis. A population-based study from Eastern Denmark","volume":"31","author":"Holmstr\u00f6m","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.bulcan.2026.03.016_bib0900","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ajh.27363","article-title":"Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation","volume":"99","author":"Gagelmann","year":"2024","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.bulcan.2026.03.016_bib0905","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.bbmt.2016.02.019","article-title":"Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis","volume":"22","author":"Robin","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2026.03.016_bib0910","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.3324\/haematol.2022.281958","article-title":"Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"108","author":"Murthy","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bulcan.2026.03.016_bib0915","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41409-024-02269-4","article-title":"Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT","volume":"59","author":"Robin","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2026.03.016_bib0920","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/10428194.2020.1827246","article-title":"Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience","volume":"62","author":"Memoli","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.bulcan.2026.03.016_bib0925","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41409-021-01222-z","article-title":"Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT","volume":"56","author":"Battipaglia","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.016_bib0930","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41409-019-0653-7","article-title":"Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis","volume":"55","author":"Shouval","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2026.03.016_bib0935","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ajh.26042","article-title":"Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: the role of the conditioning regimen","volume":"96","author":"Chiusolo","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.016_bib0940","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.bulcan.2026.03.016_bib0945","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1182\/bloodadvances.2024013451","article-title":"Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study","volume":"8","author":"Jain","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.bulcan.2026.03.016_bib0950","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/ajh.70049","article-title":"Impact of donor type on outcomes after allogeneic hematopoietic cell transplantation in myelofibrosis: a study on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"100","author":"Hern\u00e1ndez-Boluda","year":"2025","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.bulcan.2026.03.016_bib0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.04.008","article-title":"Successful outcome in patients with myelofibrosis undergoing allogeneic donor hematopoietic cell transplantation using reduced doses of post-transplantation cyclophosphamide: challenges and review of the literature","volume":"29","author":"Garc\u00eda-Cadenas","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.bulcan.2026.03.016_bib0480","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41409-021-01540-2","article-title":"Impact of donor-derived CD34+ infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT","volume":"57","author":"Czerw","year":"2022","journal-title":"Bone Marrow Transplant"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512600278X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512600278X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:49:18Z","timestamp":1781725758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512600278X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":96,"alternative-id":["S000745512600278X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.03.016","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques dans la my\u00e9lofibrose\u00a0: s\u00e9lection des patients, pr\u00e9paration pr\u00e9-greffe et harmonisation des pratiques (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}